Progestin intrauterine device in an adolescent with grade 2 endometrial cancer.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 22270425.
- Also identified by DOI 10.1097/AOG.0b013e318234d97c and PMC identifier 3266511.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The treatment of endometrial cancer in young women who desire future fertility poses several challenges. Oral progestin and progestin-releasing intrauterine devices (IUDs) have been shown to result in regression of endometrial hyperplasia and grade 1 endometrioid endometrial carcinoma. However, limited data are available on the use of these methods in women with grade 2 disease. An 18-year-old nulliparous woman was diagnosed with a grade 2 endometrial adenocarcinoma. She desired future fertility and therefore underwent placement of a levonorgestrel-releasing IUD. The patient subsequently underwent endometrial sampling every 3 months and remained disease-free 13 months after initial IUD placement. A progestin-releasing IUD may be a valid treatment option for grade 2 endometrial cancer in young women who desire to retain fertility.
Medical subject headings
- Adenocarcinoma
- Contraceptive Agents, Female
- Endometrial Neoplasms
- Intrauterine Devices, Medicated
- Levonorgestrel